Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis

• Chaim Gilon,
• Michal Klazas,
• Adi Lahiani,
• Adi Schumacher-Klinger,
• Shira Merzbach,
• Johnny N. Naoum,
• Haim Ovadia,
• Limor Rubin,
• Susan Cornell-Kennon,
• Erik M. Schaefer,
• Jehoshua Katzhendler,
• Cezary Marcinkiewicz,
• Amnon Hoffman,
• Philip Lazarovici

Affiliations

Chaim Gilon

Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel

Michal Klazas

@Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

Adi Lahiani

‡Pharmacology, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

Adi Schumacher-Klinger

@Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

Shira Merzbach

@Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

Johnny N. Naoum

Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel

Haim Ovadia

§Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Limor Rubin

&Allergy and Clinical Immunology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Susan Cornell-Kennon

AssayQuant Technologies, Inc., Marlboro, Massachusetts, United States

Erik M. Schaefer

AssayQuant Technologies, Inc., Marlboro, Massachusetts, United States

Jehoshua Katzhendler

∥Medicinal Chemistry, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

Cezary Marcinkiewicz

Department of Bioengineering, College of Engineering, Temple University, Philadelphia, Pennsylvania, United States

Amnon Hoffman

@Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

Philip Lazarovici

‡Pharmacology, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel